Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial
CNS Drugs · 2024
DOI: 10.1007/s40263-024-01122-y ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CNS Drugs, 2024. Verfasst von Lynn Marie Trotti und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Emory University School of Medicine, 12 Executive Park Dr NE, Atlanta, GA, 30329, USA. Lbecke2@emory.edu. Hauptthemen laut MEDLINE: Modafinil, Narcolepsy, Dextroamphetamine, Central Nervous System Stimulants. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCATS NIH HHS, American Academy of Sleep Medicine Foundation.
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: Although there are several treatments for narcolepsy type 2 and idiopathic hypersomnia, studies that assess amphetamines, symptoms beyond sleepiness, and comparative effectiveness are needed. We performed a randomized, fully blinded, noninferiority trial of modafinil versus amphetamine-dextroamphetamine in these disorders. METHODS: Forty-four adults were randomized to modafinil or amphetamine-dextroamphetamine, individually titrated to a maximum of modafinil 200 mg twice daily or amphetamine-dextroamphetamine 20 mg twice daily, for 12 weeks. Primary outcome was change in Epworth from baseline to week 12, with a noninferiority threshold of 2 points. Secondary outcomes were (1) patient global impression of change measures of disease severity, sleepiness, sleep inertia, and cognition; (2) change from baseline in Hypersomnia Severity Index; and (3) change from baseline in Sleep Inertia Questionnaire. Adverse events were compared between groups. RESULTS: Epworth improved 5.0 [± standard deviation (SD) 2.7] points with modafinil and 4.4 (± SD 4.7) with amphetamine-dextroamphetamine; noninferiority of amphetamine-dextroamphetamine was not demonstrated (P = 0.11). Noninferiority of amphetamine-dextroamphetamine was demonstrated for change scores of severity, sleepiness, sleep inertia, Hypersomnia Severity Index, and Sleep Inertia Questionnaire. Dropouts due to adverse events were 31.8% for modafinil (including two severe events) and 9.1% for amphetamine-dextroamphetamine, P = 0.13. Anxiety was more common with modafinil and appetite suppression with amphetamine-dextroamphetamine. CONCLUSION: Noninferiority of amphetamine-dextroamphetamine to modafinil was not demonstrated for the primary outcome. However, amphetamine-dextroamphetamine was noninferior on multiple secondary measures of disease severity and symptomatology. These data may inform shared decision-making regarding treatment for idiopathic hypersomnia and narcolepsy type 2. REGISTRATION: Clinicaltrials.gov Registration (NCT03772314) 12/10/18. .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Emory University School of Medicine, 12 Executive Park Dr NE, Atlanta, GA, 30329, USA. Lbecke2@emory.edu.
- Emory Healthcare, Emory Sleep Center, Atlanta, GA, USA. Lbecke2@emory.edu.
- Department of Neurology, Emory University School of Medicine, 12 Executive Park Dr NE, Atlanta, GA, 30329, USA.
- Emory Healthcare, Emory Sleep Center, Atlanta, GA, USA.
- Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA, USA.
ORCID-Profile: Lynn Marie Trotti
Förderung
- NINDS NIH HHS
- NCATS NIH HHS
- American Academy of Sleep Medicine Foundation
- National Center for Advancing Translational Sciences
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Trotti, L. M., Blake, T., Hoque, R., Rye, D. B., Sharma, S., & Bliwise, D. L. (2024). Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial. CNS Drugs. https://doi.org/10.1007/s40263-024-01122-y
Vancouver
Trotti LM, Blake T, Hoque R, Rye DB, Sharma S, Bliwise DL. Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial. CNS Drugs. 2024. doi:10.1007/s40263-024-01122-y
BibTeX
@article{Trotti2024,
author = {Trotti, Lynn Marie and Blake, Tyler and Hoque, Romy and Rye, David B and Sharma, Surina and Bliwise, Donald L},
title = {Modafinil Versus Amphetamine-Dextroamphetamine For Idiopathic Hypersomnia and Narcolepsy Type 2: A Randomized, Blinded, Non-inferiority Trial},
journal = {CNS Drugs},
year = {2024},
doi = {10.1007/s40263-024-01122-y}
}
EUVIMED